Patients were 18 to 56 years of age and got received a diagnosis of multiple sclerosis between 0 and 32 years before study entry. A total of 540 individuals were contained in the subgroup of patients who underwent MRI. The baseline demographic and disease features of individuals in the MRI cohort were very similar to those of individuals who were not in the MRI cohort and to those of the overall study population . A total of 952 patients finished the study . The rate of discontinuation of the study drug was similar in the three groups , as was the price of withdrawal from the analysis . The %age of patients who switched to an authorized therapy for multiple sclerosis was low . The mean duration of participation in the scholarly study was 83.9 weeks and was similar among the three groups.However, severe adverse occasions, classified according to the WHO,16 tended to occur more often in the methotrexate group, where the only death related to the scholarly study drug occurred. Low-dose methotrexate is considered to be safe for the treating patients with rheumatoid arthritis relatively.24-26 The somewhat higher level of methotrexate-associated adverse events in our trial than the rates reported for rheumatoid arthritis is most likely explained by the bigger doses prescribed for patients with Wegener’s granulomatosis or microscopic polyangiitis, a lot of whom also have impaired renal function.